Skip to main
GRI

GRI Stock Forecast & Price Target

GRI Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

GRI Bio is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing therapies for diseases linked to immune system dysregulation. The company recently reported positive top-line data from its Phase 2a study of GRI-0621 for the treatment of idiopathic pulmonary fibrosis (IPF). Additionally, GRI Bio's second planned drug product, GRI-0803, is a potential treatment for autoimmune disorders. The company's current valuation is attractive with significant upside potential, and it has a strong pipeline with a Phase 2a trial already underway and promising preclinical work in diseases like lupus and multiple sclerosis.

Bears say

GRI Bio is facing a challenging financial future due to its need to undergo multiple reverse stock splits in the next few years. Additionally, while the company's product candidates show potential for treating serious diseases, the market potential for these diseases (such as lupus and idiopathic pulmonary fibrosis) may not be large enough to generate significant revenue for the company. Furthermore, there is also competition in the market from established biotech companies, which may affect the success rate of GRI Bio's products.

GRI has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of GRI Bio Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About GRI Bio Inc (GRI) Forecast

Analysts have given GRI a Strong Buy based on their latest research and market trends.

According to 1 analysts, GRI has a Strong Buy consensus rating as of Jul 18, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $32, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $32, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

GRI Bio Inc (GRI)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.